Cornerstone Therapeutics Announces Events to Be Held at the 2013 North American
Cystic Fibrosis Conference
SALT LAKE CITY, UT -- (Marketwired) -- 10/17/13 -- Cornerstone
Therapeutics Inc. (NASDAQ: CRTX) will exhibit at the North American
Cystic Fibrosis Conference (NACFC), Oct. 17-19 at the Salt Palace
Convention Center in Salt Lake City. The annual scientific meeting,
sponsored by the Cystic Fibrosis Foundation, is designed for medical
professionals focused on CF research and patient care.
"This is our first time participating at NACFC and we are energized
by the amount of information we have to share with the CF community,"
said Craig A. Collard, Cornerstone's Chief Executive Officer. "In
less than one year's time, we have begun to unveil a portfolio of
therapeutic products, educational resources and support tools for CF
patients in the U.S. We are passionate about improving the lives of
people with CF and look forward to continuing to build our CF
portfolio and the supporting resources in the future."
As part of the conference, Cornerstone will sponsor Product Theater
sessions in the exhibit hall to give attendees an opportunity to
learn about recent developments. The events are as follows:
-- Thursday, Oct. 17 (12:10-12:30 p.m.) - Exocrine Pancreatic
Insufficiency is About More Than Just Enzymes. The clinical discussion
will be led by Steven Strausbaugh, M.D., FCCP, CPI, and Megan Hart,
M.S., R.D., L.D., from UH/Rainbow Babies & Children's (Cleveland,
OH). The session will provide an overview of PERTZYE(R)
(pancrelipase) for the treatment of exocrine pancreatic insufficiency
in patients with CF.
-- Friday, Oct. 18 (12:10-12:30 p.m.) - BETHKIS(R) (Tobramycin
Inhalation Solution) - A Concentrated Option for Nebulization, led by
Kimberly Novak, Pharm.D., B.C.P.S., pharmacy clinical specialist,
pulmonary medicine, Nationwide Children's Hospital (Columbus, OH).
BETHKIS will launch later this fall and is FDA approved for the
management of cystic fibrosis patients with Pseudomonas aeruginosa.
ABOUT PERTZYE (pancrelipase) DELAYED-RELEASE CAPSULES
PERTZYE (pancrelipase) is approved by the U.S. Food and Drug
Administration (FDA) for the treatment of exocrine pancreatic
insufficiency due to cystic fibrosis or other conditions.
Limitation of Use: PERTZYE is not interchangeable with any other
IMPORTANT SAFETY INFORMATION ABOUT PERTZYE
Fibrosing colonopathy is associated with high-dose use of pancreatic
enzyme replacement. Exercise caution when doses of PERTZYE exceed
2,500 lipase units/kg of body weight per meal (or greater than 10,000
lipase units/kg of body weight per day).
To avoid irritation of oral mucosa, do not chew PERTZYE or retain in
Hyperuricemia may develop. Consider monitoring uric acid levels in
patients with hyperuricemia, gout, or renal impairment.
There is theoretical risk of viral transmission with all pancreatic
enzyme products including PERTZYE.
Exercise caution when administering pancrelipase to a patient with a
known allergy to proteins of porcine origin.
The most common adverse reactions (≥ 10% of patients treated
with PERTZYE) are diarrhea, dyspepsia, and cough.
PERTZYE full Prescribing Information and Medication Guide are
available at www.pertzyecf.com.
ABOUT BETHKIS (Tobramycin Inhalation Solution)
BETHKIS(R) is indicated for the management of cystic fibrosis
patients with Pseudomonas aeruginosa. Safety and efficacy have not
been demonstrated in patients under the age of six years, patients
with FEV1 less than 40% or greater than 80% predicted, or patients
colonized with Burkholderia cepacia.
IMPORTANT SAFETY INFORMATION ABOUT BETHKIS
BETHKIS is contraindicated in patients with a known hypersensitivity
to any aminoglycoside.
Bronchospasm can occur with inhalation of BETHKIS. Bronchospasm and
wheezing should be treated as medically appropriate.
Caution should be exercised when prescribing BETHKIS to patients with
known or suspected auditory, vestibular, renal, or neuromuscular
dysfunction. Audiograms, serum concentration, and renal function
should be monitored as appropriate.
Avoid concurrent and/or sequential use of BETHKIS with other drugs
with neurotoxic or ototoxic potential.
BETHKIS should not be administered concurrently with ethacrynic acid,
furosemide, urea, or mannitol.
Aminoglycosides may aggravate muscle weakness because of a potential
curare-like effect on neuromuscular function.
Fetal harm can occur when aminoglycosides are administered to a
pregnant woman. Apprise women of the potential hazard to the fetus.
Common adverse reactions (more than 5%) occurring more frequently in
BETHKIS patients are forced expiratory volume decreased, rales, red
blood cell sedimentation rate increased, and dysphonia.
BETHKIS full Prescribing Information is available at www.bethkis.com
PERTZYE(R) (pancrelipase) is owned by Digestive Care, Inc. and is
licensed to Cornerstone Therapeutics for sales and marketing purposes
in the United States. BETHKIS(R) (Tobramycin Inhalation Solution) is
owned by Chiesi Farmaceutici S.p.A. and is licensed to Cornerstone
Therapeutics Inc. for sales and marketing purposes in the United
About Cornerstone Therapeutics Inc.
Cornerstone Therapeutics Inc. (NASDAQ: CRTX), headquartered in Cary,
N.C., is a specialty pharmaceutical company focused on
commercializing products for the hospital and adjacent specialty
markets. Key elements of the Company's strategy are to focus its
commercial and development efforts in the hospital and adjacent
specialty product sector within the U.S. pharmaceutical marketplace;
continue to seek out opportunities to acquire companies, marketed or
registration-stage products and late-stage development products that
fit within the Company's focus areas; and generate revenues by
marketing approved generic products through the Company's
wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. For more
information, visit www.crtx.com.
CRTX Investor Relations Contact:
Vice President, Strategy and Business Development
CRTX Media Relations Contact:
Press spacebar to pause and continue. Press esc to stop.